A new antibiotic, sorfequiline (TBAJ-876), shows promise in drastically shortening TB treatment from six months to potentially 15 weeks. In a Phase II trial, this next-gen drug achieved superior results to current standards (BPaL), demonstrating higher efficacy and a better safety profile with less cardiac toxicity.
FBI Reform - fbireform.comFBI Reform - fbireform.com - The News And Times